References
Jarvis B, Figgitt DP. Topical 3% diclofenac in 2.5% hyaluronic acid gel. Am J Clin Dermatol 2003; 4(3): 203–13
Engel A, Johnson M-L, Haynes SG. Health effect of sunlight exposure in the United States: results from the first national health and nutrition examination survey 1971–4. Arch Dermatol 1988; 124: 72–9
Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42(1 Pt 2): S23–4
Jeffes EWB, Tang EH. Actinic keratosis: current treatment options. Am J Clin Dermatol 2000; 1(3): 161–79
Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146(1): 94–100
Wolf Jr JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40(11): 709–13
Del Rosso J, Walsh K. A randomized, single-centre, double-blind, placebo-controlled study to evaluate the safety and efficacy of 3% diclofenac gel (HyalCT-1101) in the topical treatment of outpatients with actinic keratoses. [clinical trial summary, data on file]. Malvern (PA) Bioglan Pharma Inc, 2001
Bioglan Pharma Inc. Solaraze gel (diclofenac sodium-3% w/w topical gel). Prescribing information [online]. Available from URL: http://www.bioglanusa.com/productPI/solarazePI.html [Accessed 2002 Oct 3]
Rights and permissions
About this article
Cite this article
Topical 3% diclofenac gel is an effective treatment for actinic keratoses. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319090-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200319090-00001